Yu. Yu. Garmash

Yu. Yu. Garmash

Auto-generated profile, based on publicly available information

Yu. Yu. Garmash

The Moscow Research and Clinical Center for Tuberculosis Control of the Moscow Government Department of Health

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2019 in Russian Journal of Cardiology
Verified
Journal Article
Open access
MSM. V. Serova
M. V. Serova
MPMaria Poltavskaya
Maria Poltavskaya
YGYu. Yu. Garmash
Yu. Yu. Garmash
DID. A. Ivanova
D. A. Ivanova
EPEkaterina S. Pershina
Ekaterina S. Pershina
GMG. G. Melkonyan
G. G. Melkonyan

22 June 2026 in PULMONOLOGIYA
Verified
Journal Article
Closed access
ACAlexander Chuchalin
Alexander Chuchalin
SASergey Avdeev
Sergey Avdeev
AVA. A. Vizel
A. A. Vizel
ZAZaurbek Aisanov
Zaurbek Aisanov
OBO. P. Baranova
O. P. Baranova
PYP. K. Yablonskiy
P. K. Yablonskiy
Sarcoidosis is a systemic inflammatory disease of unknown etiology characterized by the formation of noncaseating granulomas, multisystem organ involvement, and T-cell activation at the site of granulomatous inflammation with the release of various chemokines and cytokines. The prevalence of sarcoidosis is 3 – 25 cases per 100,000 population. The mainstay of sarcoidosis therapy is corticosteroids, immunosuppressants, and drugs that affect oxidative stress and tumor necrosis factor. The aim of the article was to introduce the latest procedures for the diagnosis and treatment of sarcoidosis of various localizations, agreed upon in the Russian Federation. The target audience for these clinical guidelines are general practitioners, internists, pulmonologists, phthisiologists, pathologists, radiologists, and rehabilitation physicians. Methods. Each recommendation statement for diagnostic and therapeutic measures is assessed using evidence levels ranging from 1 to 5 and a recommendation strength rating scale for categories A, B, and C. The clinical guidelines also contain commentary and explanations for these recommendations, algorithms for the diagnosis and treatment of idiopathic pulmonary fibrosis, and reference materials. Conclusion. These clinical guidelines provide an overview of current knowledge on the etiology and pathogenesis, clinical manifestations, diagnosis, and treatment of sarcoidosis. These clinical guidelines were approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation in 2025.

17 April 2026 in Journal of Respiratory Medicine
Verified
Journal Article
Closed access
ACAlexander Chuchalin
Alexander Chuchalin
SASergey Avdeev
Sergey Avdeev
AVA.A. Vizel
A.A. Vizel
ZAZaurbek Aisanov
Zaurbek Aisanov
OBO.P. Baranova
O.P. Baranova
PYP.K. Yablonsky
P.K. Yablonsky
This article presents a summary of the clinical guidelines «Sarcoidosis: Federal Clinical Guidelines for Diagnosis and Treatment», developed by five scientific and practical societies and approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation.